Previous 10 | Next 10 |
Updated data from Phase 1/2 ADXS-PSA study combination arm show prolonged survival in heavily pretreated prostate cancer patients with microsatellite-stable (MSS) disease Updated early findings from Phase 1 ADXS-NEO study show encouraging safety, immunogenicity and clinical signals ...
Advaxis, Inc. (NASDAQ:ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at t...
Advaxis, Inc. (NASDAQ: ADXS) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in five upcoming industry conferences: BioNJ 9 th Annual BioPartnering Conference Date and Tim...
Gainers: Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP...
Fusion Connect (NASDAQ: FSNN ) -82% as audit problems prompt Chapter 11 analyst warning. More news on: Fusion Connect, Inc., Advaxis, Inc., AVEO Pharmaceuticals, Inc., Stocks on the move, Read more ...
Advaxis (NASDAQ: ADXS ) prices its public offering of 2.5M common stock at a price of $4.00/share, for gross proceeds of ~ $10M. More news on: Advaxis, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a ...
Gainers: PLAY +7.6% . OTCQB:HLIX +3.8% . EVC +2.8% . PTGX +2.3% . ODT +2.1% . More news on: Dave & Buster's Entertainment, Inc., Helix TCS, Inc., Entravision Communications Corporation, Stocks on the move, Read more ...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering shares of its common st...
Energy Focus (NASDAQ: EFOI ) -52% on Q4 earnings . More news on: Energy Focus, Inc., Evoke Pharma, Inc., Apyx Medical Corporation, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...